protein phosphatase 2 regulatory subunit B'gamma pseudogeneGenealiases: []
Q-omics provides the consensus-scored PPP2R5CP profile across patient tissues and cancer cell-line models. PPP2R5CP expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PPP2R5CP is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PPP2R5CP RNA expression shows 14,500 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where PPP2R5CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP2R5CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP2R5CP survival associations across molecular data types. PPP2R5CP RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP2R5CP RNA expression–survival associations across cancer types. High PPP2R5CP expression shows unfavorable associations in KIRC, UVM and LIHC, but favorable associations in SKCM, BLCA and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PPP2R5CP RNA expression.
This table summarizes PPP2R5CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPP2R5CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP2R5CP shows higher tumor expression in COAD, LIHC, KIRC, READ, UCEC and CHOL. The COAD box plot shows higher PPP2R5CP RNA expression in tumor versus normal tissue (log2 FC = +0.413, t-test p < 0.001).
This table shows molecular features associated with PPP2R5CP in patient tissues and cancer cell lines. In patient samples, PPP2R5CP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
